126 related articles for article (PubMed ID: 36006674)
1. Ruxolitinib takes center stage for VEXAS syndrome.
Conway R
Blood; 2022 Aug; 140(8):807-808. PubMed ID: 36006674
[No Abstract] [Full Text] [Related]
2. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.
Heiblig M; Ferrada MA; Koster MJ; Barba T; Gerfaud-Valentin M; Mékinian A; Coelho H; Fossard G; Barraco F; Galicier L; Bienvenu B; Hirsch P; Vial G; Boutin AB; Galland J; Le Guenno G; Bigot A; Warrington KJ; Kermani TA; Grayson PC; Patel BA; Beck DB; Jamilloux Y; Fenaux P; Sujobert P
Blood; 2022 Aug; 140(8):927-931. PubMed ID: 35609174
[TBL] [Abstract][Full Text] [Related]
3. Heiblig M, Ferrada MA, Koster MT, et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood. 2022;140(8):927-931.
Blood; 2023 Mar; 141(13):1647. PubMed ID: 36995697
[No Abstract] [Full Text] [Related]
4. Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Fetter T; Rios GC; Niebel D; Bieber T; Wenzel J
Acta Derm Venereol; 2020 May; 100(10):adv00144. PubMed ID: 32285135
[TBL] [Abstract][Full Text] [Related]
5. Off-label Studies on the Use of Ruxolitinib in Dermatology.
Tegtmeyer K; Ravi M; Zhao J; Maloney NJ; Lio PA
Dermatitis; 2021 May-Jun 01; 32(3):164-172. PubMed ID: 33443378
[TBL] [Abstract][Full Text] [Related]
6. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
Koschmieder S; Jost E; Cornelissen C; Müller T; Schulze-Hagen M; Bickenbach J; Marx G; Kleines M; Marx N; Brümmendorf TH; Dreher M
Eur J Haematol; 2020 Nov; 105(5):655-658. PubMed ID: 32593209
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
Cao Y; Wei J; Zou L; Jiang T; Wang G; Chen L; Huang L; Meng F; Huang L; Wang N; Zhou X; Luo H; Mao Z; Chen X; Xie J; Liu J; Cheng H; Zhao J; Huang G; Wang W; Zhou J
J Allergy Clin Immunol; 2020 Jul; 146(1):137-146.e3. PubMed ID: 32470486
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
Front Immunol; 2020; 11():620098. PubMed ID: 33658996
[TBL] [Abstract][Full Text] [Related]
9. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
[TBL] [Abstract][Full Text] [Related]
10. Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
Kayaoglu B; Kasap N; Yilmaz NS; Charbonnier LM; Geckin B; Akcay A; Eltan SB; Ozturk G; Ozen A; Karakoc-Aydiner E; Chatila TA; Gursel M; Baris S
J Clin Immunol; 2021 May; 41(4):769-779. PubMed ID: 33475942
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.
Kirito K; Suzuki K; Miyamura K; Takeuchi M; Handa H; Okamoto S; Gadbaw B; Yamauchi K; Amagasaki T; Ito K; Hino M
Int J Hematol; 2018 Feb; 107(2):173-184. PubMed ID: 28956263
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.
King B; Lee AI; Choi J
J Invest Dermatol; 2017 Apr; 137(4):951-954. PubMed ID: 27887955
[No Abstract] [Full Text] [Related]
13. A 61-year-old patient with Crohn's disease and severe postoperative recurrence responding to JAK inhibitor ruxolitinib for polycythemia vera treatment.
Marquès-Camí M; García-Guiñón A; Garreta J; Voltà T; Torres G; Sesé E
Gastroenterol Hepatol; 2022 Apr; 45 Suppl 1():16-17. PubMed ID: 34284085
[No Abstract] [Full Text] [Related]
14. Ruxolitinib (Opzelura) for atopic dermatitis.
Med Lett Drugs Ther; 2022 Jan; 64(1642):12-13. PubMed ID: 35134043
[No Abstract] [Full Text] [Related]
15. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
Vannucchi AM; Sordi B; Morettini A; Nozzoli C; Poggesi L; Pieralli F; Bartoloni A; Atanasio A; Miselli F; Paoli C; Loscocco GG; Fanelli A; Para O; Berni A; Tassinari I; Zammarchi L; Maggi L; Mazzoni A; Scotti V; Falchetti G; Malandrino D; Luise F; Millotti G; Bencini S; Capone M; Piccinni MP; Annunziato F; Guglielmelli P;
Leukemia; 2021 Apr; 35(4):1121-1133. PubMed ID: 32814839
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib: the first agent approved for myelofibrosis.
Verstovsek S
Clin Adv Hematol Oncol; 2012 Feb; 10(2):111-3. PubMed ID: 22402352
[No Abstract] [Full Text] [Related]
17. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.
Hunter AM; Newman H; Dezern AE; Steensma DP; Niyongere S; Roboz GJ; Mo Q; Chan O; Gerds A; Sallman DA; Dominguez-Viqueira W; Letson C; Balasis ME; Ball M; Kruer T; Zhang H; Lancet JE; List AF; Sekeres MA; Komrokji RS; Padron E
Clin Cancer Res; 2021 Nov; 27(22):6095-6105. PubMed ID: 34253584
[TBL] [Abstract][Full Text] [Related]
18. JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients.
Gallipoli P
Leuk Res; 2018 Dec; 75():71-72. PubMed ID: 30392903
[No Abstract] [Full Text] [Related]
19. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B
Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
Kołodrubiec J; Kozłowska M; Irga-Jaworska N; Sędek Ł; Pastorczak A; Trelińska J; Młynarski W
Leuk Res; 2022 Oct; 121():106925. PubMed ID: 35939887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
